Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Vitamin D insufficiency is currently defined as a serum level 25-hydroxy vitamin D that is less than 75 nmol/l. (And there are many who think that a higher minimum level might be appropriate.)
Filed under: Living with Prostate Cancer, Management, Prevention | Tagged: insufficiency, prevalence, vitamin D | 8 Comments »
Every year tens of thousands of men newly diagnosed with prostate cancer are given a bone scan (and other types of scan) as part of their “normal” diagnostic work-up. The only value of the bone scan is that it is able to identify men who already have (or at least may have evidence suggesting) actual [...]
Filed under: Diagnosis, Management, Risk | Tagged: bone scan, Diagnosis, guideline, work-up | 6 Comments »
A new article has stimulated an important and public discussion about how to report the quality of outcomes of patients who receive a radical prostatectomy (RP) — and therefore how to communicate the probabilities of specific outcomes of a certain quality to new patients considering radical prostatectomy as a first-line treatment option.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: outcome, pentafecta, radical prostatectomy, standards, trifecta | 4 Comments »
In an announcement this morning that will shake up the innovation end of the cancer radiotherapy business, Accuray, Inc. (which makes and markets the CyberKnife system for stereotactic body radiation therapy) has agreed to acquire TomoTherapy, Inc. (which integrates CT imaging with conformal radiation therapy).
Filed under: Uncategorized | Tagged: Accuray, CyberKnife, radiation therapy, TomoTherapy, Varian | Leave a Comment »
Dendreon’s production ramp-up for sipuleucel-T (Provenge®) is on track, the company says, with manufacturing expected to be up to full speed by year’s end. All three US-based manufacturing plants will be shipping by then, and treatment with Provenge should be available at hundreds of more locations, according to a Reuters report last week.
Filed under: Living with Prostate Cancer, Management | Tagged: access, Provenge, sipuleucel-T | Leave a Comment »
One of the problems with the PSA test is that it identifies a possible risk for prostate cancer in many men each year who are subsequently shown — by prostate biopsy — to be at no risk for the actual clinical condition.
Filed under: Diagnosis, Risk | Tagged: biopsy, Diagnosis, gene, profiling, risk | Leave a Comment »
A while back now the research group at M. D. Anderson Cancer Center initiated a Phase II clinical trial of a drug called tandutinib in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) who had already had taxane-based chemotherapy.
Filed under: Drugs in development, Living with Prostate Cancer | Tagged: castration-resistant, mCRPC, PDGF, PDGFR, platelet-derived growth factor, receptor, tandutinib | Leave a Comment »
The standard form of treatment for a man with a rising PSA after a first-line radical prostatectomy (RP) is salvage radiation therapy (with or without a period of androgen deprivation). However, an Italian group has just published pilot data on the use of high-intensity focused ultrasound (HIFU) as salvage therapy after RP.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: HIFU, pilot, radical prostatectomy, salvage | Leave a Comment »
Patients and others with a strong interest in understanding the ways in which new drugs like abiraterone acetate and MDV3100 are likely to change the way we treat advanced forms of prostate cancer might be interested in a webcast based on a satellite symposium held at the recent Genitourinary Cancers Symposium in Orlando.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, castration-resistant, CRPC, MDV3100 | Leave a Comment »
A team of researchers at the University of Michigan Comprehensive Cancer Center are claiming that they have identified an important target that may lead to the development of effective treatments for one aggressive type of prostate cancer. The target is a gene called SPINK1.
Filed under: Diagnosis, Risk | Tagged: aggressive, Diagnosis, gene, risk, SPINK1 | 2 Comments »
Two recent papers from a clinical research team at the University of Western Ontario in Canada have offered us insights into the appropriate usage of cryoablation as salvage therapy for men with progressive (recurrent) prostate cancer after first-line treatment for localized and locally advanced prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: cryotherapy, outcome, prognosis, salvage | Leave a Comment »
Many prostate cancer patients will recognize statements made by other patients and reported in a study just published in Cancer Nursing and also available on the Medscape Oncology platform. Interestingly this study comes from a group of Norwegian nurses who built an online e-mail support system for their prostate cancer breast cancer patients.
Filed under: Living with Prostate Cancer, Management | Tagged: education, information, nursing, on-line, support | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site